MAP2K7 and cancer: The drugs that are most advanced clinically are the MEK inhibitors, as exemplified by trametinib and selumetinib.7,8 Inhibition of MEK kinases in cancer cells has been shown to trigger complex feedback loops and pathway cross talk that can modulate drug responses (reviewed in ref. 25).